NEW YORK (360Dx) – A team of researchers at the University of Utah is developing a point-of-care platform using alpha-fetoprotein, a biomarker already in use in laboratory tests, to detect liver cancer. They have built a proof-of-concept system made possible by a nanoplasmonic coating that amplifies its signal and enhances its level of detection, the researchers said.
University of Utah Developing Nanoplasmonic Test Targeting Liver Cancer Detection at Point of Care
Premium
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.